Integrated Advisors Network LLC Sells 27,540 Shares of Insulet Co. (NASDAQ:PODD)

Integrated Advisors Network LLC lessened its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 41.9% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 38,229 shares of the medical instruments supplier's stock after selling 27,540 shares during the period. Integrated Advisors Network LLC owned 0.05% of Insulet worth $10,039,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Horizon Investments LLC raised its stake in shares of Insulet by 3.1% in the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier's stock worth $362,000 after acquiring an additional 42 shares during the last quarter. Wilmington Savings Fund Society FSB increased its holdings in shares of Insulet by 9.6% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier's stock valued at $140,000 after purchasing an additional 47 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in Insulet by 2.3% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier's stock worth $552,000 after purchasing an additional 48 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in Insulet by 5.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier's stock worth $274,000 after buying an additional 50 shares in the last quarter. Finally, Sequoia Financial Advisors LLC increased its stake in shares of Insulet by 2.4% in the 4th quarter. Sequoia Financial Advisors LLC now owns 2,170 shares of the medical instruments supplier's stock valued at $566,000 after buying an additional 50 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PODD. Barclays raised their target price on shares of Insulet from $234.00 to $266.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. Canaccord Genuity Group raised their price objective on shares of Insulet from $304.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a report on Friday, May 30th. Piper Sandler raised their price target on Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Finally, Citigroup reaffirmed a "buy" rating and set a $380.00 price objective (up from $320.00) on shares of Insulet in a research note on Thursday, May 22nd. Three investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $318.41.

Insulet Stock Down 0.5%

Insulet stock traded down $1.38 during mid-day trading on Thursday, reaching $300.86. The stock had a trading volume of 224,678 shares, compared to its average volume of 711,059. The firm has a market capitalization of $21.17 billion, a PE ratio of 51.96, a price-to-earnings-growth ratio of 3.62 and a beta of 1.37. Insulet Co. has a fifty-two week low of $173.00 and a fifty-two week high of $329.33. The stock's 50-day simple moving average is $285.05 and its 200-day simple moving average is $274.43. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. The business had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company's quarterly revenue was up 28.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.73 EPS. On average, sell-side analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the sale, the senior vice president now directly owns 23,180 shares of the company's stock, valued at $7,382,134.60. This represents a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now owns 3,231 shares of the company's stock, valued at $888,525. This represents a 36.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.